For research use only. Not for therapeutic Use.
CL075 (3M002) is a selective TLR8 agonist with immunomodulating properties. CL075 triggers a MyD88-dependent signaling pathway to elicit production of inflammatory cytokines and type I interferons (IFNs) via activation of NF-κB and IRF7, respectively[1][2][3].
CL075 (2 μM; 4 h) induces the production of IL-6, IL-8, and IFN-γ in rabbit splenocytes[1].
CL075 (2 μM; 48 h) induces the total IgM production and cell proliferation in rabbit splenocytes[1].
CL075 (2 μM; 7 h) activates the rabTLR8 in 293 cells[1].
CL075 (5 μM (0.5 mL); s.c.) activates a mild antigen-specific antibody response in rabbits[1].
| Catalog Number | I011586 |
| CAS Number | 256922-53-9 |
| Synonyms | 2-propyl-[1,3]thiazolo[4,5-c]quinolin-4-amine |
| Molecular Formula | C13H13N3S |
| Purity | ≥95% |
| InChI | InChI=1S/C13H13N3S/c1-2-5-10-16-11-12(17-10)8-6-3-4-7-9(8)15-13(11)14/h3-4,6-7H,2,5H2,1H3,(H2,14,15) |
| InChIKey | NFYMGJSUKCDVJR-UHFFFAOYSA-N |
| SMILES | CCCC1=NC2=C(S1)C3=CC=CC=C3N=C2N |
| Reference | [1]. Lai CY, et, al. TLR7/8 agonists activate a mild immune response in rabbits through TLR8 but not TLR7. Vaccine. 2014 Sep 29;32(43):5593-9. [2]. Spranger S, et, al. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol. 2010 Jul 1;185(1):738-47. [3]. Maalej KM, et, al. TLR8, but not TLR7, induces the priming of the NADPH oxidase activation in human neutrophils. J Leukoc Biol. 2015 Jun;97(6):1081-7. |
